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STATE-OF-THE-ART CLINICAL ARTICLE 
Application of Polymerase Chain Reaction to the Diagnosis of Infectious Diseases 
David N. Fredricks and David A. Relman From the Division of Infectious Diseases, Department of Medicine and 
Department of Microbiology and Immunology, Stanford University, 
Stanford, and the Veterans Affairs Palo Alto Health Care System, 
Palo Alto, California 
PCR and other sequence-based microbial detection methods, 
once considered to be only research tools, are being used 
increasingly in the clinical microbiology laboratory. As this 
technology expands into the clinical arena, clinicians will need 
to learn its advantages and limitations so that sound judgments 
can be made. Astute clinicians know that results of blood 
culture reports, whether positive or negative, must be inter- 
preted using an understanding of the test employed and an 
assessment of the clinical scenario. Similarly, infectious dis- 
eases practitioners will need to expand their understanding of 
PCR-based diagnostics so that these powerful tests are used 
appropriately. 
It is our goal to make PCR-based diagnostics understandable 
to clinicians. We will point out the limitations of conventional 
diagnostic methods for infectious diseases, discuss the advan- 
tages and limitations of PCR-based methods, and mention 
some current and future applications of this technology. We 
will not discuss every current or pending application of PCR to 
diagnostic microbiology; the reader is referred to other publi- 
cations for additional details [1-3]. We emphasize the princi- 
ples behind PCR-based diagnosis, and acknowledge a research- 
oriented bias in our viewpoint. 
The limitations of existing diagnostic methods and the potential 
of PCR-based detection and identification methods are demon- 
strated by a case from Stanford University Medical Center. 
A Case of Meningitis 
A 53-year-old woman was seen in the emergency depart- 
ment with a 5-hour history of severe headache and depressed 
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mental status. On physical examination, she had a fever (tem- 
perature to 38.6?C), nuchal rigidity, and no evidence of a rash. 
Multiple generalized seizures were noted. Therapy with ceftri- 
axone and vancomycin was instituted in the emergency depart- 
ment for empiric treatment of meningitis, and a CT scan of the 
brain was obtained prior to a lumbar puncture. Blood cultures 
were obtained after antibiotics had been started, because of 
difficulty with phlebotomy. The lumbar puncture demonstrated 
cloudy CSF with an elevated pressure, a WBC count of 17,500 
cells/mm3 (93% neutrophils), a protein level of 756 mg/dL, and 
a glucose level of 41 mg/dL (serum glucose level, 209 mg/dL). 
Examination of a gram-stained smear of the CSF was re- 
ported to show many WBCs and many gram-negative diplo- 
cocci, suggesting the diagnosis of meningococcal meningitis. 
The patient ran a day care center, and the county health 
department was notified so that antibiotic prophylaxis could be 
started for case contacts. The patient's vancomycin was dis- 
continued, and penicillin was added to the ceftriaxone therapy 
for optimal coverage of Neisseria meningitidis. 
On the second hospital day, the gram stain of the CSF was 
reviewed. The laboratory concluded that the gram-negative 
organisms seen on the smear had a coccobacillary morphology 
more consistent with Haemophilus influenzae than with 
N. meningitidis. The penicillin was discontinued and ceftriax- 
one was continued. The patient's condition improved and she 
was discharged on the fifth day to complete a course of out- 
patient intravenous ceftriaxone. All blood and CSF cultures 
were negative. Latex agglutination tests performed on the CSF 
were negative for Haemophilus group b, Streptococcus pneu- 
moniae, group B Streptococcus, and N. meningitidis antigens. 
The etiology of this patient's meningitis was not confirmed 
using conventional methods of cultivation and antigen detec- 
tion. To identify the bacterium responsible for this patient's 
illness, we used a sequence-based approach in our laboratory. 
A sample of the patient's CSF was centrifuged to concentrate 
bacteria, and the pellet was digested to liberate bacterial DNA. 
This DNA was used as template in a broad-range PCR assay 
designed to copy enzymatically (amplify) a portion of the 
bacterial 16S rRNA gene in vitro using a thermostable DNA 
polymerase. Oligonucleotide primers complementary to 
broadly conserved regions of the 16S rRNA gene were used to 
amplify segments of the gene that also contained variable, 
phylogenetically informative DNA sequence(s) (figure 1). The 
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sequence of the amplified product was then determined using 
an automated DNA sequencer, and aligned with other known 
16S rRNA gene sequen s from bacteria present in the Gen- 
fingerprint, and can be used to identify an unknown agent or 
infer its evolutionary relationships with other previously char- 
acterized organisms. In our assay, samples of CSF and water 
used as negative controls did not produce a PCR product, 
indicating lack of bacterial DNA template. On the other hand, 
CSF from the patient with meningitis produced a PCR product. 
?ank ? , r.. : 0, . .. 
Sequencing and phylogenetic analysis showed that the organ- 
ism present in the patient's CSF matched that of H. influenzae 
biotype III [4]. 
Why did the conventional microbiological diagnostic meth- 
ods fail in this case? Although microscopy (e.g., gram staining) 
may suggest an etiologic agent, it rarely provides definitive 
evidence of infection due to a particular species. In this case, 
microscopy initially misidentified the organism as consistent 
with N. meningitidis. Fortunately, the clinicians continued 
broad spectrum antibiotics while awaiting culture confirmation 
of the organism, and therefore continued to treat for the H. in- 
fluenzae responsible for this patient's meningitis. Had ceftri- 
axone been stopped and penicillin used alone, the outcome may 
have been distinctly less favorable. Clearly the microscopic 
morphology of organisms may be misleading, with conclusions 
influenced by the training and subjective interpretation of the 
microscopist. In other cases, the number of organisms may be 
too low for visual detection by microscopy. The failure of CSF 
and blood cultures to provide a diagnosis in this case can be 
ascribed to the use of antibiotics before obtaining the culture 
samples. In the setting of meningitis, where the rapid initiation 
of antibiotics is paramount, this scenario is not unusual, espe- 
cially when a lumbar puncture is delayed because a head CT is 
ordered. However, there are cases of bacterial meningitis in 
which cultures fail to yield the organism, even without the 
institution of antibiotics, further demonstrating the limitations 
of culture-based technology. The CSF latex agglutination test 
for H. influenzae group b antigen was negative in this case, 
probably because the responsible Haemophilus species did not 
possess group b antigen, as has been noted for other biotype III 
isolates. 
Limitations of Conventional Diagnostic Methods 
Cultivation 
For more than a century, the standard diagnostic test in 
infectious diseases has been in vitro cultivation using artificial 
media. Even today, clinical microbiology laboratories devote a 
majority of their effort towards cultivation of clinical samples, 
which is a testament to the continued utility of cultivation 
technology. For microbes that are easily tamed in the petri dish, 
the sensitivity, specificity, ability to determine antibiotic sus- 
ceptibility and other clinically relevant behavioral characteris- 
tics, and intrinsic amplification of cultivation make this ap- 
proach attractive. Certain microbes may require special culture 
media and conditions, so failure to consider these microbes 
may yield negative culture results. Cultivatable microbes may 
also fail to grow after exposure to antibiotics or after poor 
sample handling, rendering a culture-independent approach 
valuable in some circumstances. Similarly, cell culture can be 
used to detect some viruses and intracellular microbes, but the 
cost, labor, and time required for this approach beg for better 
diagnostic methods. 
In contrast, other microbes are not so easily tamed in the 
laboratory. Certain pathogens such as Bartonella henselae are 
fastidious, and other human pathogens such as Mycobacterium 
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Figure 2. Percentage of cultivated and uncultivated bacteria from 
several selected bacterial divisions present in the ARB sequence 
database. From [5] (used with permission). 
leprae and Treponema pallidum continue to defy our attempts 
at cultivation on artificial media. Efforts to grow viruses such 
as human papillomavirus and hepatitis C virus in cell culture 
have been equally frustrating. Why do these microbes resist our 
cultivation attempts? Answers to this question remain obscure. 
However, a more appropriate question may be "why are we 
successful in getting so many human pathogens to grow in the 
laboratory?" 
It seems less surprising that there are culture-resistant human 
pathogens when one considers the situation in environmental 
microbiology. It is estimated that <1% of the bacteria present 
on earth have been described to date using cultivation technol- 
ogy. When environmental niches are sampled to determine the 
bacterial census, sequence-based techniques usually reveal 
large numbers of microbes that fail to grow using standard 
cultivation techniques; these organisms tend to be previously 
uncharacterized. Figure 2 illustrates the relatively high percent- 
age of uncultivated bacteria present in several selected cosmo- 
politan bacterial divisions, even in those divisions such as the 
proteobacteria, actinobacteria, and low G+C gram positives 
that contain known human pathogens. Of 36 bacterial divisions 
noted by Hugenholtz, Goebel, and Pace in their review, 13 
divisions are composed entirely of uncultivated organisms [5]. 
Therefore, we should be mindful of the limitations of cultiva- 
tion technology, and should not be surprised when sequence- 
based methods reveal novel microbes associated with human 
disease. 
Other pathogens, such as mycobacteria and fungi, will grow 
in the laboratory but may require prolonged periods of culti- 
vation. In many cases, the delay between obtaining a culture 
and the generation of a result necessitates empiric antibiotic 
therapy, sometimes lasting for months. For these slow-growing 
microbes, a cultivation-independent method would offer the 
potential for rapid diagnosis. There are several potential ad- 
vantages to a speedy diagnosis. First, one might reduce the use 
of empiric antibiotics, which in turn could help reduce antibi- 
otic selection pressures and the emergence of antibiotic resis- 
tance. Second, with more specifically directed antimicrobial 
therapy, it is likely that antibiotic costs would drop and clinical 
outcomes would improve. These issues need to be addressed 
with careful studies. 
Another problem with cultivation in the laboratory is that 
certain organisms constitute a health threat to laboratory work- 
ers who attempt to propagate them. Organisms such as Fran- 
cisella tularensis and Coccidioides immitis are notorious 
causes of outbreaks among workers in the clinical microbiol- 
ogy laboratory. These highly infectious microbes must be han- 
dled in biological safety hoods or sent out to reference labo- 
ratories where such facilities exist. Unfortunately, these 
microbes are sometimes isolated from patients who are not 
suspected of harboring such highly infectious pathogens, and, 
therefore, appropriate precautions are not used. A sequence- 
based diagnostic method could identify these hazardous mi- 
crobes without risk, since samples can be treated to kill mi- 
crobes while preserving nucleic acid for analysis. 
Finally, successful cultivation of a microbe does not neces- 
sarily imply successful identification of the microbe. Organ- 
isms isolated on artificial media must still be identified, tradi- 
tionally by using phenotypic tests such as the ability to 
metabolize sugars or growth in the presence of certain chem- 
icals or antibiotics. Although usually successful, these pheno- 
typic tests have limited discriminatory power in identifying 
microbes, the results for a given microbe may vary depending 
on the state of the organism, and they are not always repro- 
ducible and they are usually nonquantitative. For instance, the 
cell wall composition of an organism may vary depending on 
the selection of growth media. 
Serology 
Serologic assays based on the detection of host-derived 
antibodies or microbe-derived antigens have several limita- 
tions. Serologic detection of antibodies may not be helpful in 
the very acute stage of illness, because the host may not have 
time to mount an antibody response. For rapidly evolving 
diseases, the host may succumb to infection before antibodies 
can be produced. The immunocompromised host may never 
mount an appropriate antibody response to infection, again 
limiting the utility of serologic assays. Detection of microbial 
antigens requires a relatively large microbial burden, which 
limits assay sensitivity. Unlike cultivation, which detects broad 
groups of microbes, serologic assays must be ordered individ- 
ually and target narrow groups of organisms. In addition, 
serologic assays require specific and reliable antisera or anti- 
gens, which may not be available. If the clinician does not think 
of the correct serologic test to order, the diagnosis is not made. 
Microscopy/Histology 
The direct detection of microbes in tissues or fluids by 
microscopy has limited sensitivity and specificity. A relatively 
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large number of microbes must be present before they will be 
visible by microscopy (e.g., 10,000 bacteria per milliliter of 
fluid). Even if the organisms are present in sufficiently high 
concentrations, one must use the appropriate stains and condi- 
tions (e.g., darkfield for treponemes) to make them visible. As 
with serology, if one fails to consider a particular microbe, then 
one may miss that organism when using standard techniques. 
For instance, one will have difficulty visualizing B. henselae 
with a tissue gram stain, but may see the organism with a 
Warthin-Starry silver stain or with immunohistochemical 
methods. The limited specificity of microscopy reflects our 
meager ability to speciate organisms based on morphology. To 
identify microbes by direct examination, one is dependent on 
the training and experience of the microscopist, the correct 
choice of stain and illumination, and the presence of large 
numbers of organisms. These multiple variables conspire to 
make direct examination a poor diagnostic test in many situa- 
tions. 
In our case of meningitis, all three conventional diagnostic 
methods failed to identify the responsible organism. Is this just 
an isolated case, or is there a problem with our diagnostic 
armamentarium? Pneumonia is the most common infectious 
cause of death in the United States, with 4 million cases per 
year [6, 7]. No etiologic agent can be identified in >35% of 
cases of community-acquired pneumonia when using conven- 
tional diagnostic methods such as cultivation and serology. 
Better diagnostic methods are needed. 
PCR 
PCR is an enzyme-driven process for replicating DNA in 
vitro. Using this technology, one is capable of turning a few 
molecules of DNA into large quantities. Why is it useful to 
have large amounts of microbial DNA available for study? The 
levels of microbial DNA present in clinical samples are fre- 
quently too low for meaningful manipulation and measure- 
ment. PCR can produce sufficient amounts of DNA so that 
microbes can be detected and identified. Because each unique 
microbe has a unique complement of DNA (or RNA), DNA 
can function as a molecular fingerprint to help identify mi- 
crobes. Certain DNA sequences (e.g., bacterial 16S rDNA) are 
particularly informative, allowing one to distinguish most mi- 
crobes from one another. 
In the PCR, a segment of DNA is copied in vitro by a 
thermostable DNA polymerase enzyme in the presence of 
buffer, magnesium, deoxyribonucleoside triphosphates, and 
primers. Oligonucleotide primers complementary to regions on 
the coding and the noncoding strand of the DNA template are 
responsible for specificity in the reaction, determining which 
region of DNA becomes amplified. As the primers anneal to 
their complementary regions of DNA, DNA polymerases at- 
tach to the primer-template complexes and extend the DNA 
strands, producing a copy of the DNA. Each copy of DNA may 
then serve as another template for further amplification. Mul- 
tiple rounds of heating and cooling of the reaction mixture in a 
thermal cycler produce rounds of melting of double-stranded 
DNA, annealing of primer to single-stranded templates, and 
extension of DNA strands, to produce a logarithmic increase in 
DNA. In the ideal scenario, the primers chosen in the PCR are 
specific for a particular microbial gene, and hence do not 
amplify nonspecific targets such as human genes. Theoreti- 
cally, one could start with a single copy of the target microbial 
gene present in the reaction, and generate billions of copies of 
DNA from that gene. 
Although PCR is the best known and most widely used 
nucleic acid amplification technology, there are other amplifi- 
cation technologies in use. These technologies include the 
transcription-based amplification system, strand displacement 
amplification, ligase chain reaction, and Qf3 replicase system. 
In addition, there are methods such as branched DNA technol- 
ogy that do not amplify the DNA, yet can detect low levels of 
DNA via signal amplification from a probe. We will not 
discuss these other techniques further; the reader is referred to 
other sources for more in-depth information [3]. 
There are several approaches for using PCR to detect mi- 
crobial DNA. The simplest approach is specific PCR. Here, one 
designs primers that are complementary to a DNA target that is 
specific for the microbe being assayed. For instance, by select- 
ing unique regions of the Whipple bacillus' 16S rRNA gene, 
one can create primers that will amplify only the 16S rRNA 
gene from the Whipple bacillus, Tropheryma whippelii. 
In contrast, with broad-range PCR one attempts to detect a 
broader group of organisms by designing primers that are 
complementary to conserved regions of a particular gene that 
are shared by a given taxonomic group. For instance, one could 
design primers that are complementary to regions of the 16S 
rRNA gene that are shared by most members of the bacterial 
domain, with the intention of using the more variable regions 
of the amplified sequence for identification or phylogenetic 
assessment [8]. In this situation, one would expect to amplify 
any bacterial 16S rDNA present in the reaction. Between the 
extremes of specific and domain-wide PCR is a large middle 
ground of taxon-restricted PCR. Here, one designs primers that 
are complementary to conserved regions of a gene from a 
particular group of organisms; either the primers are not com- 
plementary to the same gene segment in other microbes outside 
the group or the distribution of the gene itself is limited to that 
group. For instance, primers have been designed that will 
amplify a segment of the DNA polymerase gene from all 
members of the herpesvirus family, but will not amplify DNA 
polymerase genes from other viral families. 
Another variation of PCR is multiplexing, in which multiple 
specific PCR assays are run simultaneously in the same reac- 
tion tube to test for multiple different DNA templates. In 
multiplex PCR, several sets of primers are added to the reaction 
in order to generate several different PCR products. For in- 
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stance, one could have a PCR assay designed to detect bacterial 
DNA in CSF that uses five different specific PCR reactions in 
one tube, with primer pairs directed toward S. pneumoniae, 
N. meningitidis, H. influenzae, Listeria monocytogenes, and the 
group B Streptococcus. In such an assay, some method of 
postamplification analysis is needed to determine which organ- 
ism is represented in a positive reaction. If the amplification 
products differ in size, then gel electrophoresis will provide an 
initial idea of which PCR reaction(s) took place. This approach 
is sometimes hampered by interference between primers within 
the same reaction. 
Nesting of PCR increases assay sensitivity and can increase 
specificity as well. In nested PCR, one uses the product of a 
primary PCR reaction as template in a second PCR reaction. 
The first PCR reaction amplifies a microbial DNA target using 
primers complementary to the organism or group of organisms 
being assayed. In the second round, a sample of the first PCR 
is added to fresh reaction mixture for a second PCR using a set 
of primers that anneal to regions of the same gene, but at sites 
internal to the previous priming sites. For instance, the first 
round reaction may produce a 400-bp product, and the second 
round may produce a 200-bp product that is a subset of the 
400-bp product. (In hemi-nested PCR, one primer from the first 
round is used in the second round reaction as well.) Increased 
sensitivity is obtained because the target is enriched in the first 
round of PCR, with subsequent dilution of other DNA and 
inhibitors. Additional specificity results from the set of specific 
primers employed in the second round. Even if nonspecific 
amplification occurs in round one, the nonspecific amplifica- 
tion product will probably not participate as template in the 
second round because it is unlikely to have regions of DNA 
complementary to the second set of specific primers. The 
problem with nested PCR is that it is highly prone to contam- 
ination with amplification products, and thus must be per- 
formed with extreme care and interpreted with even greater 
caution. The usual efforts to inactivate amplification products 
in order to prevent contamination do not work with nested PCR 
because one needs to use amplifiable template from the first 
round in round two. Opening PCR reaction tubes after round 
one and transferring amplification products to new tubes are 
conducive to contamination. 
How does one detect an RNA target, such as rRNA or a 
segment from the genome of an RNA virus? A modification of 
PCR called reverse transcriptase PCR (RT-PCR) can be used. 
In RT-PCR, an RNA template is the initial target, and reverse 
transcriptase creates a complementary DNA copy of the RNA. 
Oligonucleotide primers catalyze conversion of a specific seg- 
ment of RNA into DNA. Once the DNA template forms, it can 
be amplified as in standard PCR. 
Confirmation and Identification of PCR Products 
After completing a PCR, one must determine if the intended 
PCR amplification product was generated. The most commonly 
used method for detecting PCR products in the research lab has 
been gel electrophoresis. The contents of the PCR are loaded 
into an agarose or acrylamide gel, an electrical gradient is 
applied through a buffer solution, and the products migrate 
through the gel matrix. The amplification products migrate 
though the gel according to size, with smaller products travel- 
ing farther in the gel because they experience less resistance. 
When DNA fragments of known size are run in the same gel 
(as size standards), the size of the PCR amplification products 
can be estimated after the DNA is visualized (e.g., using 
ethidium bromide staining and illumination with ultraviolet 
light). A given set of primers should generate a PCR product of 
a particular size, and the appearance of an amplification prod- 
uct of the appropriate size in a gel is consistent with a positive 
PCR. Unfortunately, there are examples in which a PCR prod- 
uct of the appropriate size is generated, but the product is not 
the intended amplification product. This occurs because of 
mispriming, in which the primers anneal to sites in the genome 
(human or microbial) other than the intended target sequences, 
and generate a PCR product that happens to be similar in size 
to the intended product. 
Because nonspecific amplification products may be gener- 
ated in a PCR, the identity of the products should be confirmed. 
Confirmatory methods include sequencing of the amplification 
product, annealing of a specific oligonucleotide probe to a 
region of the amplification product that spans the priming sites 
(e.g., Southern hybridization, slot blotting, probe ELISA, and 
hybridization protection assays), single-stranded conforma- 
tional polymorphism analysis, or restriction enzyme cleavage 
of the amplification product (using an enzyme known to cut a 
specific sequence within the intended product) with gel elec- 
trophoresis of the digest (restriction fragment length polymor- 
phism [RFLP] analysis). Although sequencing of the PCR 
product is the most rigorous method of confirming amplifica- 
tion product identity, it is also the most time consuming and 
laborious. Most commercial methods are likely to use an oli- 
gonucleotide probe in an ELISA format, as this will provide a 
rapid yet highly specific method of detecting a PCR product 
and confirming its identity. The TaqMan system (Perkin-Elmer 
Applied Biosystems, Foster City, CA) uses a fluorescently 
labeled probe to detect, confirm, and quantify the PCR product 
as it is being generated in real time (figure 3) [9]. This system 
obviates the need for postamplification detection and confir- 
mation of product, and therefore reduces assay time. Probe- 
based confirmation methods also have the advantage of detect- 
ing small quantities of amplification products, and thus offer 
superior sensitivity. 
Another method used to characterize and identify PCR prod- 
ucts employs nucleotide sequences attached to solid supports, 
such as filters or glass slides. With so-called DNA chip tech- 
nology, or high density DNA microarrays, one can quantitate 
and characterize fluorescently labeled mRNA or DNA by al- 
lowing it to hybridize to a complementary DNA sequence(s) 
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Figure 3. Real time detection of the human 3-actin gene using 
TaqMan PCR reagents (PE Applied Biosystems, Foster City, CA) and 
a Smart Cycler high speed thermocycler (Cepheid, Sunnyvale, CA). Y 
axis = FAM (6-carboxyfluorescein) fluorescence intensity (volts), x 
axis = PCR cycle number. A fluorescent probe is released from the 
P-actin PCR product and detected during PCR. Squares = 1,000,000; 
triangles = 100,000; open circles = 10,000; closed circles = 1,000; 
open bar = 100; X = 10; closed bar = 0 gene copies. Higher amounts 
of starting target DNA require fewer PCR cycles before product is 
detected (courtesy of Linda Western, Cepheid). 
anchored to the surface, and subsequent fluorescence scanning 
[10, 11]. Tens or hundreds of thousands of sequences (probes) 
can be placed within a surface area of 1 cm2. DNA microarrays 
have been used to measure in a simultaneous, semiautomated 
fashion the mRNA expressed by all Saccharomyces cerevisiae 
genes, and -20% of all expressed human genes. In another 
application not yet realized one could immobilize thousands of 
probes (e.g., 16S rDNA) for different bacterial divisions, gen- 
era, and species at a high density. Amplification products from 
clinical samples subjected to broad-range 16S rDNA PCR and 
incorporating a fluorophore could then be analyzed by com- 
parative hybridization, using this chip to determine which 
bacterium or bacteria are present in the sample. The speed and 
power of DNA chip technology combined with PCR should not 
be underestimated. 
Advantages of PCR Over Conventional Diagnostic 
Methods 
PCR-based assays for the detection of microbial DNA can be 
extremely sensitive. Under the right conditions, one can am- 
plify a single copy of a microbial DNA gene or gene fragment 
from a clinical sample and detect it. If the microbe contains 
multiple gene copies per organism, then one microbe may 
provide multiple targets for amplification. For instance, the 
bacterium Escherichia coli contains seven copies of the 16S 
rRNA gene per organism, so even a fraction of an E. coli (e.g., 
a lysed organism) may be detectable by PCR. Even greater 
assay sensitivity can be achieved by amplifying microbial 
targets that are present in large numbers within a single mi- 
crobe. One bacterium may contain thousands of 16S rRNA 
copies that are incorporated into ribosomes and can serve as 
targets in an RT-PCR assay. In one example, an RT-PCR assay 
was designed for the detection of T. pallidum 16S rRNA [12]. 
Using Southern hybridization to detect the PCR product, the 
investigators were able to detect 1/100 RNA equivalents of an 
organism in CSF. It may be possible that this RT-PCR assay 
could even detect a single organism that has lysed and liberated 
its rRNA into the CSF, although the half-life of rRNA in CSF 
is not known. Although studies of the clinical utility of this 
RT-PCR assay have not been published, the assay could rev- 
olutionize the diagnosis of neurosyphilis, since other diagnostic 
methods are insensitive (CSF VDRL) or too cumbersome (rab- 
bit inoculation). 
In addition to unrivaled sensitivity, PCR offers the potential 
for remarkable specificity. Specificity in PCR derives from the 
fact that each distinct microbe has unique DNA. One can 
design oligonucleotide primers complementary to these unique 
segments of DNA, so that only microbial DNA from the 
organism being sought is amplified. Alternatively, one can 
design oligonucleotide primers complementary to conserved 
regions of microbial DNA so as to detect more diverse groups 
of organisms. If the DNA amplified with this broad-range 
approach contains intervening segments of DNA that are 
unique to specific microbes, then these microbes can be iden- 
tified using techniques such as sequencing or restriction en- 
zyme analysis. An example of a phylogenetically informative 
gene that can be used for both organism-specific PCR as well 
as broad-range PCR is the bacterial 16S rRNA gene, as previ- 
ously mentioned. When using sequence information to identify 
a microbe, one avoids the need to grow the organism or 
maintain the organism in a particular physiologic state for 
metabolic analysis. Although a microbe may switch certain 
metabolic traits on and off, leading to confusion when trying to 
identify the microbe using traditional phenotypic tests, the 
genetic fingerprint of the microbe remains fairly constant, 
offering a more reliable method of microbial identification. 
Another advantage to PCR-based microbial detection and 
identification is speed. PCR can be completed in minutes to 
hours. Simple methods to confirm the identity of the amplifi- 
cation product can also be completed in minutes to hours. 
Therefore, a turnaround time of one day is not unrealistic for 
many types of assays. Cultivation of microbes tends to take 
hours to days for initial propagation, and hours to days for 
phenotypic diagnostic testing. Even a rapidly growing organ- 
ism, such as E. coli in blood culture, requires days of laboratory 
time before definitive identification is made using cultivation 
methods with phenotypic testing. We are all familiar with cases 
in which a patient dies soon after an acute, nonspecific flu-like 
illness but before an organism can be grown in culture, such as 
with meningococcal sepsis. These cases remind us that for 
easily cultivatable organisms, culture is sometimes too slow to 
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be useful. This knowledge inevitably leads to the increased use 
of empiric antibiotics, even for illnesses that ultimately prove 
to be viral in origin, and to the emergence of antibiotic resis- 
tance. A more rapid and sensitive diagnostic test for infection, 
such as PCR, might reverse this trend toward empiricism if the 
correct microbes could be identified early in the infection, and 
if this test had a high negative predictive value [13]. 
Problems and Limitations of PCR 
False Positives 
Ironically, false positive reactions are the Achilles' heel of 
PCR and stem from its greatest strength, namely the incredible 
sensitivity of enzymatic amplification. False positive results 
occur because PCR may amplify "contaminating" DNA that 
finds its way into a sample, even when that DNA is present in 
infinitesimally small amounts. DNA contaminates samples 
through several means. 
The most important means of contamination is through am- 
plification product carryover. A single PCR can generate bil- 
lions of DNA copies, each of which is capable of acting as 
target for a future PCR reaction. If even a submicroscopic 
portion of a positive amplification reaction gets into the envi- 
ronment where subsequent PCR reactions are mixed, then false 
positive reactions may ensue. PCR reagents, pipettes, pens, 
tubes, tube racks, hands, and door handles (almost any object) 
are capable of harboring or transmitting PCR amplification 
products. To reduce the risks of false positive reactions from 
amplification product carryover, laboratories are usually phys- 
ically divided into pre-PCR and post-PCR rooms. Some labo- 
ratories also have a separate room for specimen digestion and 
processing. All materials and personnel are supposed to flow 
one way, from pre-PCR to post-PCR rooms. Thus, once a PCR 
reaction is set up in the pre-PCR area, it is moved to the 
post-PCR area where amplification and product analysis are 
performed. Materials are not allowed into the pre-PCR room 
unless they are new or have been decontaminated. Some labs 
have separate gowns or disposable gowns for each area. 
Amplification product carryover contamination can also be 
eliminated or reduced by using some inactivation techniques. 
In one method, deoxyuridine triphosphate (dUTP) is used as a 
substrate in PCR instead of deoxythymidine triphosphate 
(dTTP). Before each PCR, the reaction mixtures are treated 
with the enzyme uracil N-glycosylase to render any contami- 
nating (i.e., uracil containing) DNA incapable of amplification. 
The uracil N-glycosylase is then inactivated before proceeding 
with PCR. Thymidine remains intact in the sample DNA, and 
is used as template for new uracil-containing amplification 
products. In another method, the PCR reactions contain dTTP 
and isopsoralen, and are treated with ultraviolet light after the 
amplification step [14]. Thymine dimers form between thymi- 
dine bases, rendering the DNA incapable of further amplifica- 
tion. These methods do not work well for PCR products of 
-100 bp or less in size. 
One approach for monitoring amplification product car- 
ryover contamination in samples or solutions employs primers 
that contain additional signature oligonucleotides at the 5' end 
of each primer in order to make tagged amplification products. 
Bases at the 3' ends of the primers bind to their complementary 
bases in the target DNA, providing specificity in the PCR. The 
signature sequences at the 5' end become incorporated into 
PCR products but do not anneal to target. When a sample is 
positive, it can be re-tested in a PCR assay using primers that 
are complementary to the signature sequences. Amplification 
with the signature sequence primers proves that the sample 
contains previously amplified target, since native target does 
not contain this signature sequence and therefore will not 
amplify. Unfortunately, this method cannot monitor for epi- 
sodic contamination from items such as gloves or pipettes, 
which may introduce amplification products into a reaction 
without directly contaminating the original sample or solutions. 
However, running samples in replicate and repeating PCR 
assays should reveal problems with episodic contamination. 
False positive reactions may also be caused by intersample 
contamination. A clinical sample may have large quantities of 
target DNA present. When opening this sample, DNA may 
contaminate gloves or other items in the environment, leading 
to the inadvertent introduction of DNA into other PCR reac- 
tions where it is amplified. This problem can be minimized by 
changing gloves between handling of samples, duplicating 
sample analysis, and avoiding aerosol generation. This problem 
can be detected by interspersing negative control reactions with 
the test samples to see if these controls are positive. Amplifi- 
cation product inactivation will not control this problem be- 
cause the contaminating DNA has not been previously ampli- 
fied. 
Another cause of false positive reactions occurs in the setting 
of broad-range PCR, e.g., when amplifying the bacterial 16S 
rRNA gene with consensus primers. With primers that are 
complementary to highly conserved bacterial 16S, or fungal 
18S rDNA sequences and highly sensitive reaction conditions, 
one may detect microbial DNA uniformly. The negative con- 
trols are positive because the PCR reagents, such as water and 
Taq polymerase, contain small amounts of bacterial DNA. It is 
very difficult to eliminate all contaminating DNA, especially 
from the polymerase enzyme. If one looks carefully, it is 
possible to detect small fragments of bacterial 16S rDNA in 
many "sterile" solutions, such as water for injection, and un- 
inoculated blood culture media [15]. Just because a solution is 
sterile does not mean that it is free of microbial DNA, only that 
no microbes can be cultivated. For highly sensitive, broad- 
range PCR applications, we may need to create a new standard 
for cleanliness in our reagents that measures microbial DNA 
instead of colony-forming units. 
A more subtle problem with false positives may arise from 
the detection of small quantities of microbial DNA in clinical 
samples. If PCR is more sensitive than culture in some situa- 
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tions, then we may need to define what constitutes a "signifi- 
cant" level of microbial DNA for a given clinical situation. For 
instance, what does it mean if S. pneumoniae DNA is detected 
in a blood sample? Although the presence of pneumococcal 
DNA in blood would seem to suggest an invasive infection, 
this may not always the case. In one study, when blood samples 
from healthy subjects were examined by PCR, 17% were 
positive for pneumococcal DNA (samples from children, not 
those from adults) [16]. As with other tests, clinical correla- 
tions will need to be made to see in what situations PCR offers 
an improvement in diagnostic capabilities, and to determine 
what levels of microbial DNA are significant for a given 
organism, site, and situation. 
False Negatives 
PCR assays for the detection of microbes may be falsely 
negative for several reasons. The sample may contain PCR 
inhibitors that interfere with amplification. Samples that have 
been shown to contain PCR inhibitory substances include 
blood (heme), blood culture media, urine, vitreous humor, and 
sputum. The PCR inhibitors must be diluted, removed, or 
inactivated in order to amplify any microbial DNA present. 
DNA purification methods help to remove many of these 
inhibitors, although some inhibitors persist when standard pu- 
rification protocols are used. Samples may also be falsely 
negative because the digestion step has failed to release the 
microbial DNA present or because the DNA has been lost in 
the purification step. Microbes with thick cell walls, such as 
fungi or bacterial spores, may be difficult to break open and 
therefore may require additional mechanical or enzymatic lysis 
steps in order to liberate microbial DNA for amplification. 
Amplification of a human gene can help monitor for PCR 
inhibitors and check the quality of the DNA present in a sample 
of human tissue subjected to PCR for the detection of mi- 
crobes. For instance, if PCR using primers complementary to 
the human j-globin gene fails to yield a PCR product with a 
human tissue sample, then that sample is problematic. The 
problem sample should be checked for the presence of PCR 
inhibitors and DNA. If a tissue sample is 3-globin PCR neg- 
ative, then a negative result in a microbial DNA PCR assay has 
no meaning, since amplifiable DNA may not be present. If a 
sample is ,3-globin PCR positive but microbial DNA PCR 
negative, then the sample is more likely a "true" negative for 
microbial DNA. Obviously, this approach will not work with 
any procedure in which human DNA is removed (e.g., see 
sequence capture below and [17]). Some PCR kits contain an 
internal amplification standard that allows one to monitor in- 
hibitory activity and test performance in each sample. 
PCR-based assays may also be negative because of analysis 
of an inadequate sample volume. Large volumes of fluid can be 
cultivated, such as 10-20 mL of blood. On the other hand, 
sample volumes are usually very small with PCR, in the range 
of 1-10 /IL, which are added to a reaction volume of 20-100 
jiL. If one bacterium is present in 1 mL of blood, then culti- 
vation of 10 mL of blood has a good chance of detecting the 
organism (assuming that the organism is cultivatable). PCR 
that is performed on purified DNA from a digest of 0.1 mL of 
the same blood concentrated to 10 juL may not detect the 
organism, depending on the sensitivity of the assay and the 
number of gene copies of target present in the bacterium. 
To increase the sensitivity of PCR assays, microbial DNA 
can be concentrated, such as with sequence capture PCR [17]. 
In this technique, microbial DNA is bound to complementary 
capture oligonucleotides, which in turn are bound to a solid 
support. Unbound DNA and inhibitory substances from the 
sample are washed away. The concentrated, purified microbial 
DNA is then used for PCR. 
Sample Acquisition and Preparation 
One should be mindful that the sample collection process 
can have a significant impact on the outcome of the PCR assay. 
Tissues and fluids should be refrigerated and rapidly processed, 
or stored frozen in order to preserve the DNA for amplification. 
Nucleases present in fluids can degrade DNA, so storage in a 
magnesium-free nvironment (e.g., with EDTA), at low tem- 
peratures, or in chaotropic solutions is helpful. In the field, 
where freezers are not available, tissues can be stored in 
ethanol or a chaotropic solution such as guanidine isothiocya- 
nate. Fixation of tissues in formaldehyde and other pathologi- 
cal fixative solutions can damage DNA, particularly with pro- 
longed fixation times. Fixation should be avoided if samples 
are being collected prospectively for PCR analysis. 
When using broad-range PCR, such as with conserved 16S 
rDNA primers, one must be careful in selecting the tissue and 
anatomical site of acquisition. Broad-range bacterial PCR will 
detect normal bacterial flora, and thus should be applied to 
tissues that are usually free of bacteria such as blood, CSF, and 
brain. Broad-range PCR using tissues that are normally in 
contact with bacteria, such as the mouth, colon, and skin, 
makes interpretation of the results challenging because multi- 
ple PCR products may be generated. When a heterogeneous 
collection of PCR products is generated, these must be indi- 
vidually identified to sort out which sequence comes from a 
pathogen, and which sequence comes from a normal colonizer. 
There are many protocols for sample digestion and DNA 
purification. Some digestion methods employ mechanical 
means such as freezing-thawing, sonication, agitation with 
glass beads or ceramic particles, or crushing with mortar and 
pestle. Other methods use chemical or enzymatic means to 
break open microbes, such as using chaotropes, detergents, 
proteases, or other enzymes active on microbial cell walls. 
Some methods or combinations work well for selected mi- 
crobes, but there is presently no universal method optimized 
for digesting all microbes in all tissues. Similarly, certain DNA 
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purification protocols work well with certain samples. This is 
unfortunate because one would like to have a universal diges- 
tion and DNA purification protocol that one could use in the 
clinical microbiology lab for all samples destined for PCR. 
Semiautomated DNA and RNA purification systems are avail- 
able for use in the clinical microbiology laboratory. 
Cost 
PCR is expensive. For example, our clinical microbiology 
laboratory charges $125 for a herpes simplex virus (HSV) PCR 
assay using CSF. The cost of PCR reagents and equipment is 
substantial. The requirement for separate pre-PCR and post- 
PCR areas means that molecular microbiology laboratories use 
a disproportionate share of laboratory space. Furthermore, 
there are training costs associated with teaching microbiolo- 
gists to perform these molecular diagnostic assays. Will PCR- 
based assays ever compete with traditional diagnostic methods 
such as cultivation and serology? 
For certain diagnostic tests, such as HSV PCR for the 
diagnosis of encephalitis, PCR is currently more cost effective 
than previous diagnostic approaches (see below and [18]). The 
advantages to PCR-based tests, such as speed and sensitivity, 
may offset higher diagnostic costs by reducing hospitalization 
and treatment costs. However, these indirect cost advantages 
are difficult to quantify. As the budgets of clinical microbiol- 
ogy labs continue to shrink, administrators will look to the 
more easily quantifiable bottom line of the laboratory, and will 
demand that PCR-based assays be cost competitive with other 
diagnostic methods. The direct costs of PCR-based diagnostics 
will likely decrease as this technology becomes more refined. 
Some PCR assays such as the Chlamydia and Neisseria gon- 
orrhoeae assays have direct costs in the $8-10 range and are 
already cost competitive with culture technology. Miniaturiza- 
tion of PCR reactions and the use of high throughput robotics 
technology will likely lead to substantial cost reductions. In- 
creased use of PCR-based methods may also reduce costs 
through competition and reduced labor costs. For certain mi- 
crobes, PCR is the only diagnostic approach, and thus there is 
no basis for a cost comparison. For instance the Whipple 
bacillus, T. whippelii, cannot be detected using methods such 
as culture and serology, leaving PCR as the most definitive 
diagnostic test, although histology and electron microscopy of 
tissues may also suggest the diagnosis. 
Antibiotic Susceptibility and Resistance 
PCR amplification of phylogenetically informative se- 
quences such as the 16S rRNA gene fails to provide data about 
the antibiotic susceptibility of the organism. One advantage of 
cultivation is that a susceptibility profile can usually be deter- 
mined in order to help guide treatment. For organisms with 
stable antibiograms, this function is less important. For organ- 
isms that are prone to developing resistance, the lack of sus- 
ceptibility data is problematic. Yet PCR can play a role in 
determining antibiotic susceptibility. PCR assays have been 
designed for the detection of antibiotic resistance genes in 
microbes, such as the methicillin resistance gene (mecA) in 
Staphylococcus aureus and mutations in the rifampin resistance 
gene (rpoB) in Mycobacterium tuberculosis. Although the 
presence of a resistance gene in a microbe does not always 
imply expression of that gene and phenotypic resistance, its 
absence does imply a lack of resistance through that particular 
genetic mechanism. In the future, multiplex PCR or microarray 
technology may help to identify both the microbe and deter- 
mine antibiotic susceptibility profiles in one reaction. 
PCR in Practice: HSV PCR for the Diagnosis of Herpes 
Encephalitis 
An excellent example of an organism-specific PCR-based 
assay is HSV PCR for the diagnosis of herpes simplex enceph- 
alitis (HSE). The previous gold standard for the diagnosis of 
HSE was brain biopsy with cell culture. The cost and morbidity 
of this diagnostic test were high, mostly related to the need for 
general anesthesia and craniotomy. The significant effort re- 
quired to make the diagnosis by brain biopsy led some clini- 
cians to treat patients empirically with acyclovir rather than 
pursue the diagnosis. Although there is little toxicity associated 
with acyclovir, the lack of a definitive diagnosis may have 
hindered further diagnostic evaluation of patients having other 
causes of encephalitis. 
With HSV PCR, CSF is obtained from the patient by lumbar 
puncture and assayed, avoiding the need for the more invasive 
brain biopsy. CSF is added to a PCR reaction mixture contain- 
ing primers that are complementary to regions in the DNA 
polymerase gene or the glycoprotein B gene of HSV-1 and 
HSV-2. The assay can detect about 20 gene copies of either 
herpesvirus. The presence of HSV DNA in the CSF of a patient 
with encephalitis is sufficient to make the diagnosis of HSE. 
This test is more rapid than culture and is sensitive and specific. 
It is less costly (considering that the costs of surgery and 
anesthesia run into thousands of dollars), less invasive, and 
produces less morbidity and mortality than does brain biopsy. 
Given the advantages of PCR for the diagnosis of HSE, there 
is now little reason to perform brain biopsies on patients 
suspected of having this diagnosis. 
The HSV PCR assay provides an example of how difficult it 
can be to compare a new diagnostic test to a gold standard 
when the gold standard is not very golden. In one study that 
compared PCR to biopsy with culture, 53 of 54 biopsy-proven 
patients with HSE were also positive by PCR (98%) [18]. It is 
of interest that three of 47 biopsy negative patients were found 
to be PCR positive (6%). How does one interpret the results 
when a novel test (PCR) picks up more cases than the gold 
standard (brain biopsy)? Are the additional cases false positives 
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with the new diagnostic test, or false negatives with the gold 
standard? Review of the laboratory and clinical data from this 
study suggests that the positive PCR results in these biopsy 
negative patients are true positives that are due to errors in 
sample acquisition that led to negative culture results (e.g., 
placing the brain in formalin before culture). Because HSE can 
be a patchy process, biopsy may miss areas of involvement. If 
the three PCR positive but biopsy negative cases are considered 
to be true positives, then HSV PCR is the more sensitive test in 
this study. HSV PCR for the diagnosis of HSE will likely 
become the new gold standard. 
Specific PCR Assays 
A number of commercially available PCR assays have been 
designed for the detection of specific microbes [1, 2]. These 
assays use primers that are complementary to unique stretches 
of DNA present in a given microbe's genome. Assays are 
available for a variety of pathogens, including HIV, HSV, 
hepatitis B virus, hepatitis C virus, cytomegalovirus, enterovi- 
rus, Chlamydia trachomatis, M. tuberculosis, Mycobacterium 
avium complex, T. whippelii, and Neisseria gonorrhoeae. 
Three of these assays are discussed below. 
RT-PCR is used to detect viral load in an assay of HIV RNA 
(MONITOR, Roche, Branchburg, NJ). The target is a segment 
of the HIV- 1 gag gene. The assay normally detects as few as 50 
gene copies per milliliter of plasma after ultracentrifugation of 
the sample to concentrate virions, and can be used to monitor 
the effectiveness of antiretroviral therapy. The PCR product 
binds to a probe-coated microwell plate, and a colorimetric 
assay quantitates the target. A modified target, called a quan- 
titation standard, is added to the reaction so that HIV copy 
number can be determined. Plasma should not be collected in 
heparin, as it is a PCR inhibitor. 
A PCR assay for C. trachomatis targets a segment of a 
cryptic plasmid, and is able to detect 10 plasmid copies, or 1 
inclusion-forming unit (Amplicor, Roche). The assay is so 
sensitive that urine can be used to screen patients for infection, 
avoiding the need for more invasive examination, and thereby 
facilitating the acquisition of patients' samples. PCR is more 
sensitive than cell culture. A culture should still be obtained 
when collecting legal evidence, such as for cases of rape or 
child abuse, as PCR results may not be legally acceptable proof 
of infection. Endocervical and urethral swabs can also be 
tested. The assay does not detect plasmid-free variants of 
C. trachomatis, and urine should not be frozen, but stored in a 
refrigerator. Spermicide and surgical lubricant can act as PCR 
inhibitors, producing false negative reactions. 
A PCR assay is available that detects a segment of the 
T. whippelii 16S rRNA gene for the diagnosis of Whipple's 
disease (Mayo Clinic, Rochester, MN). The assay can detect 
<100 copies/mL of sample fluid. PCR is more sensitive than 
histology for diagnosis. PCR is also more useful than histology 
for monitoring response to antibiotic therapy because histo- 
logic resolution of intestinal esions may take months to years, 
whereas PCR-based evidence of infection tends to correlate 
with disease resolution or relapse [19]. 
Broad-Range PCR 
Bacteria isolated by cultivation can be identified using a 
commercially available broad-range 16S rDNA PCR assay 
with sequencing of the amplification product. This genotypic 
identification method was shown to be superior to other (phe- 
notypic) methods of microbial identification when applied to a 
series of fastidious aerobic gram-negative bacilli [20]. How- 
ever, broad-range PCR for the direct detection of microbial 
DNA in clinical specimens remains an experimental approach 
[8]. This approach is hobbled by the presence of contaminating 
DNA in PCR reagents, which prevents the use of very sensitive 
PCR conditions. In addition, when multiple organisms are 
present in a sample, direct sequencing of the amplification 
product cannot be performed because there are mixed ampli- 
fication products. These multiple sequence types must be dis- 
tinguished by methods such as cloning, single-stranded con- 
formational polymorphism analysis, or group-specific probe 
hybridization. Broad-range consensus PCR with direct se- 
quencing can be successfully applied to clinical samples that 
contain a single organism. 
The gene targets that have been successfully used in broad- 
range consensus PCR assays for the identification and phylo- 
genetic characterization of microbes include the small subunit 
ribosomal RNA genes (16S rDNA in prokaryotes, and 18S 
rDNA in eukaryotes), the citrate synthase gene, and heat shock 
protein genes. Phylogenetically informative gene targets 
should have regions of sequence conservation for the design of 
broad-range primers, and areas of sequence diversity to distin- 
guish between organisms. The value of a gene target for 
broad-range PCR depends in part on the diversity and number 
of microbial sequence types from that target present in data- 
bases, as well as the reliability of that locus in reflecting 
organismal evolutionary history. For the small subunit rRNA 
gene, there are >9,000 sequences from different organisms 
present in databases, making this a useful gene for identifying 
a microbe or determining its close evolutionary neighbors. 
Primers have been described for broad-range bacterial or fun- 
gal PCR assays, but there are no primers that can detect all 
groups of viruses. There is too much sequence diversity in viral 
genes to design a broad-range viral consensus PCR assay. 
However, one can design primers complementary to conserved 
genes segments in certain viral families, such as the DNA 
polymerase gene of herpesviruses. 
The Future of PCR: Technical Advances 
Advances in nucleic acid amplification technology will make 
future diagnostic tests faster and less expensive [21]. PCR has 
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been miniaturized so that nanoliter quantities of sample are 
processed within a few minutes. For instance, high speed, 
continuous flow PCR has been performed on a glass microchip 
in which the sample is moved rapidly between thermostated 
temperature zones [22]. Using this microdevice, 20 cycles of 
PCR could be performed in as little as 90 seconds. Similarly, 
small-volume, rapid PCR has been performed in microcapillary 
tubes and micromachined silicon chip-based reaction cham- 
bers. The disadvantage of small volume PCR for the detection 
of microbes is that organisms present in low concentrations in 
a sample may be missed. This limitation can be overcome by 
sample preparation methods that concentrate microbial nucleic 
acids, or by continuous flow/multiple sampling methods that 
increase the volume of sample analyzed. The advantages of 
small-volume PCR include reduced cost from the use of fewer 
reagents, and the ability to analyze numerous aliquots from a 
clinical sample so that multiple tests can be performed on a 
limited volume of tissue or fluid. 
Another advance in PCR-based diagnostics is real time de- 
tection of PCR products. For instance, the TaqMan system [9] 
uses a fluorescently labeled probe and the exonuclease activity 
of Taq polymerase to monitor the formation of product as it is 
being generated (figure 3). Real time detection methods can be 
combined with miniaturized, rapid PCR technologies. With 
currently available technology, it is possible to design a mi- 
crochip or microcapillary PCR apparatus that can amplify, 
detect, and characterize a microbial DNA target within min- 
utes. 
Questions without Answers 
The application of PCR to the detection of microbes in 
clinical samples raises several questions. How long does mi- 
crobial DNA persist in tissues after disease resolution or anti- 
biotic treatment? Does microbial DNA from some microbes 
persist in certain tissues or body fluids after viable organisms 
are gone? Does microbial DNA increase in the blood after lysis 
of organisms at a distant tissue site, such as with use of cell 
wall active antibiotics? Is the presence of bacterial RNA a 
better indicator of current infection with viable organisms than 
bacterial DNA? What is a clinically significant level of micro- 
bial DNA at a particular site? How can PCR distinguish be- 
tween colonization, latent infection, active infection, and re- 
lapsing infection? Is microbial DNA routinely found in 
"sterile" sites sampled from normal individuals? 
A few animal studies have attempted to address these ques- 
tions. With a mouse model of Lyme disease, investigators were 
able to show by PCR that Borrelia burgdorferi DNA disap- 
peared from tissues immediately after a 5-day antibiotic treat- 
ment course, and that the PCR results correlated with culture 
results [23]. This study suggests that the response to antibiotics 
for Lyme disease might be monitored by PCR. Similarly, 
investigators using a chinchilla model of otitis media found a 
strong correlation between PCR results and culture results 
when animals were injected with viable H. influenzae. When 
animals were injected with purified bacterial DNA or with 
killed bacteria, the amplifiable DNA rapidly disappeared [24]. 
In a rabbit model of syphilis in which live or heat-killed 
T. pallidum was injected into the skin and testes, heat-killed 
treponemes were no longer detectable by PCR after 15-30 
days, whereas viable organisms were detected by PCR for 
months [25]. These studies suggest that bacterial DNA is 
cleared from the tissue sites of animals after bacterial death, but 
that the DNA from different microbes may have different 
elimination kinetics at different sites. 
Human studies looking at the persistence of microbial DNA 
by PCR are few, but include a study of pulmonary tuberculosis 
treatment hat showed that sputum smears and cultures for M. 
tuberculosis convert to negative before PCR results, but that 
PCR results do correlate with clinical response to antibiotics 
and also can predict relapse. It is not clear if the persistent PCR 
signal seen in some of these patients is due to low levels of 
viable organisms, or due to amplifiable DNA from nonviable 
organisms [26]. A study of PCR for the detection of T. palli- 
dum in CSF from patients with neurosyphilis suggests that 
bacterial DNA may persist for years after antibiotic treatment 
[27]. However, the episodically positive PCR results from this 
study may instead be due to false positive reactions, since the 
investigators used a nested PCR assay with its high potential 
for contamination. A study of HSV PCR for herpes encepha- 
litis suggested that HSV DNA may persist in CSF for 2-3 
weeks after initiation of effective treatment [18]. 
Answers to these questions will require clinicians and re- 
searchers to compare carefully PCR-based microbial detection 
methods with existing diagnostic methods. Only with further 
experience will the benefits and limitations of PCR become 
fully apparent. 
Conclusions 
PCR is a powerful technique that is increasingly applied to 
the diagnosis of infectious diseases. PCR-based assays detect 
microbial nucleic acid in clinical samples and do not require 
growth of the organism. PCR-based assays can be fast, sensi- 
tive, and specific, but may also be associated with technical 
problems such as false positive reactions due to sample con- 
tamination, and false negative reactions due to the presence of 
PCR inhibitors in the sample. As the cost of PCR reagents 
decline, and as the number of PCR-based applications increase, 
the clinical microbiology laboratory of the future will look 
increasingly like a molecular biology laboratory. Panels of 
PCR assays are likely to be developed, targeting microbes 
involved in specific syndromes such as pneumonia, meningitis, 
and diarrhea. Rather than having to grow an intact microbe, one 
will be able to "grow" a segment of its DNA, replacing culture 
media with PCR reaction mix, and the incubator with the 
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thermal cycler. PCR-based diagnostic tests offer clinicians a 
powerful new weapon to add to their quivers. We are long 
overdue for rapid, sensitive diagnostic tests in infectious dis- 
eases that allow clinicians to make sound judgments in real 
time. The diagnosis of Rocky Mountain spotted fever should be 
confirmed within hours of presentation, not days later at au- 
topsy, or weeks later in convalescence. PCR and other molec- 
ular diagnostic methods hold the hope of making rapid diag- 
nosis and directed therapy a reality. 
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